Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Emergent BioSolutions Inc.

Emergent BioSolutions Inc. (EBS) Stock Overview

Explore Emergent BioSolutions Inc.’s financial performance, market position, analyst ratings, and future outlook.

EBS●NYSE
HealthcareDrug Manufacturers - Specialty & Generic
$5.08
$0.26(5.39%)
U.S. Market opens in 41h 31m

Emergent BioSolutions Inc. (EBS)

Meyka AI Score

Z

Key Financials

Market Cap262.4M
P/E Ratio-1.46
EPS (TTM)$1.44
ROE-0.36%
Fundamental Analysis

AI Price Forecasts

1 Month$2.91
3 Months$8.82
1 Year Target$9.57

EBS Stock Analysis & Investment Overview (NYSE)

Our AI-powered analysis of Emergent BioSolutions Inc. (NYSE: EBS) gives investors deep insight into how the stock performs on the NYSE exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Emergent BioSolutions Inc.'s NYSE-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of EBS on the NYSE shows an RSI of 34.47, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $9.57 for the NYSE listing.

Key metrics behind Emergent BioSolutions Inc.'s NYSE-traded stock include a P/E ratio of -1.46 and a market capitalization of 262.4M. Combined with our AI analysis, these give both institutional and retail investors a clear view of EBS on the NYSE.

Price Performance (NYSE: EBS)

1-Day Change
5.50%
5-Day Change
13.00%
1-Month Change
-33.53%
3-Month Change
-39.25%
6-Month Change
-53.48%
Year-to-Date (YTD) Change
-58.86%
1-Year Change
-45.44%
3-Year Change
6.83%
5-Year Change
-92.01%
All-Time (Max) Change
-56.54%

Contact Information

https://www.emergentbiosolutions.com
240 631 3200
400 Professional Drive, Gaithersburg, MD, 20879

Company Facts

9,000 Employees
IPO DateNov 15, 2006
CountryUS
Actively Trading

Frequently Asked Questions